# US 2015/0031668 A1 · Chroman derivatives as trpm8 inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0031668 A1
- Document ID: US20150031668A1
- Status: Published application
- Kind: A1
- Application number: 14/331,426
- Filed: 2014-07-15
- Published: 2015-01-29
- Earliest claimed: 2013-07-18
- Assignees: Amgen Inc.
- Applicants: Amgen Inc.
- Inventors: Kaustav Biswas; Jian J. Chen; Vijay Keshav Gore; Scott Harried; Daniel B. Horne; Matthew R. Kaller; Vu Van Ma; Kelvin Sham; James Brown; Wenge Zhong; Thomas T. Nguyen
- Web page: https://patentgrep.com/patent/US20150031668A1

## CPC

- C07D 491/052: the oxygen-containing ring being six-membered
- C07D 471/04: Ortho-condensed systems
- C07D 498/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Chroman compounds and derivatives of Formula I are useful inhibitors of TRPM8. Such compounds are useful in treating a number of TRPM8 mediated disorders and conditions and may be used to prepare medicaments and pharmaceutical compositions useful for treating such disorders and conditions. Examples of such disorders include, but are not limited to, migraines and neuropathic pain. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.

## Claims

### Claim 1

A compound of Formula I having the structure:
a pharmaceutically-acceptable salt thereof, a tautomer thereof, a pharmaceutically-acceptable salt of the tautomer, a stereoisomer thereof, or a mixture thereof, wherein:
V is selected from —C(═O)— or —S(═O)2—;
W is absent or is selected from —NH—, —NR1a—, or O;
X1 is selected from —CR5— or —N—;
X2 is selected from —CR5— or —N—;
X3 is selected from —CR5— or —N—;
X4 is selected from —CR5— or —N—;
Y is selected from —O—, —CH2—, —NH—, —NR1b—, —CF2—, —C(═O)—, —C(H)(F)—, or —C(H)(OH)—;
Z1 is selected from —CR6— or —N—;
Z2 is selected from —CR6— or —N—;
Z3 is selected from —CR6— or —N—;
wherein 0, 1, or 2 of X1, X2, X3, and X4 are N;
wherein 0, 1, or 2 of Z1, Z2, and Z3 are N;
m is 0, 1, or 2;
R1 is C1-6alk or a direct-bonded, C1-2alk-linked, C1-2alkO-linked, saturated, partially-saturated or unsaturated 3-, 4-, 5-, 6- or 7-membered monocyclic or 7-, 8-, 9-, 10- or 11-membered bicyclic ring containing 0, 1, 2, 3 or 4 heteroatoms selected from N, O and S, but containing no more than one O or S atom, the C1-6alk and ring being substituted by 0, 1, 2 or 3 substituents independently selected from halo, oxo, C1-6alk, C1-6alkOH, C1-6alkOH substituted by 1, 2, or 3 halo substituents, C1-6alk-C(═O)Ra, C1-6alk-C(═O)ORa, C1-4haloalk, cyano, nitro, —C(═O)Ra, —C(═O)ORa, —C(═O)NRaRa, —C(═O)NRaS(═O)2Ra, —C(═NRa)NRaRa, —ORa, —OC(═O)Ra, —OC(═O)NRaRa, —OC(═O)N(Ra)S(═O)2Ra, —OC2-6alkNRaRa, —OC2-6alkORa, —SRa, ═S, —S(═O)Ra, —S(═O)2Ra, —S(═O)2NRaRa, —S(═O)2N(Ra)C(═O)Ra, —S(═O)2N(Ra)C(═O)ORa, —S(═O)2N(Ra)C(═O)NRaRa, —NRaRa, —N(Ra)C(═O)Ra, —N(Ra)C(═O)ORa, —N(Ra)C(═O)NRaRa, —N(Ra)C(═NRa)NRaRa, —N(Ra)S(═O)2Ra, —N(Ra)S(═O)2NRaRa, —NRaC2-6alkNRaRa and —NRaC2-6alkORa, wherein the ring is additionally substituted by 0 or 1 directly bonded, SO2 linked, C(═O) linked or CH2 linked saturated, partially-saturated or unsaturated 3-, 4-, 5-, 6- or 7-membered monocyclic ring containing 0, 1, 2, 3 or 4 heteroatoms selected from N, O and S, but containing no more than one O or S atom, and substituted by 0, 1, 2 or 3 groups selected from halo, oxo, C1-6alk, C1-4haloalk, cyano, nitro, —C(═O)Ra, —C(═O)ORa, —C(═O)NRaRa, —C(═NRa)NRaRa, —ORa, —OC(═O)Ra, —SRa, —S(═O)Ra, —S(═O)2Ra, —S(═O)2NRaRa, —NRaRa, and —N(Ra)C(═O)Ra;
R1a is C1-6alk;
R1b is C1-6alk or —C(═O)Rb;
R2 is H or C1-6alk;
R3 is H, C1-8alk, C1-8alkOH, C1-4haloalk, halo, cyano, Rb, —C(═O)Rb, —C(═O)ORb, —C(═O)NRaRa, —C(═NRa)NRaRa, —ORa, —OC(═O)Rb, —OC(═O)NRaRa, —OC2-6alkNRaRa, —OC2-6alkORa, —SRa, —S(═O)Rb, —S(═O)2Rb, —S(═O)2NRaRa, —NRaRa, —N(Ra)C(═O)Rb, —N(Ra)C(═O)ORb, —N(Ra)C(═O)NRaRa, —N(Ra)C(═NRa)NRaRa, —N(Ra)S(═O)2Rb, —N(Ra)S(═O)2NRaRa, —NRaC2-6alkNRaRa or —NRaC2-6alkORa;
R4 is H, C1-6alk, —C1-3haloalk, —OC1-6alk, —OC1-3haloalk, —N(C1-6alk)C1-6alk, —NHC1-6alk, —NC(═O)C1-6alk, —N(C1-6alk)C1-6alk, F, Cl, Br, CN, OH or NH2; or R3 and R4 together form a four-atom unsaturated bridge containing 0 or 1 N atoms, wherein the bridge is substituted by 0, 1 or 2 R5 substituents;
R5 is, at each instance, independently selected from H, C1-8alk, C1-8alkOH, C1-4haloalk, halo, cyano, —C(═O)Rb, —C(═O)ORb, —C(═O)NRaRa, —C(═NRa)NRaRa, —ORa, —OC(═O)Rb, —OC(═O)NRaRa, —OC2-6alkNRaRa, —OC2-6alkORa, —SRa, —S(═O)Rb, —S(═O)2Rb, —S(═O)2NRaRa, —NRaRa, —N(Ra)C(═O)Rb, —N(Ra)C(═O)ORb, —N(Ra)C(═O)NRaRa, —N(Ra)C(═NRa)NRaRa, —N(Ra)S(═O)2Rb, —N(Ra)S(═O)2NRaRa, —NRaC2-6alkNRaRa or —NRaC2-6alkORa;
R6 is, at each instance, independently selected from H, halo, ORE, C1-6alk, or CF3;
R7 and R8 are independently selected from H or C1-6alk, or R7 and R8, together with the carbon atom to which they are attached, join to form a 3 to 7 membered cycloalkyl ring or a 3-7 membered heterocyclyl ring that includes 1 or 2 heteroatoms selected from O, N, or S;
R9 and R16 are, at each instance, independently selected from H or C1-6alk;
Ra is independently, at each instance, H or Rb; and
Rb is independently, at each instance, phenyl, benzyl or C1-6alk, and when R3 is Rb, Rb may additionally be an unsaturated 5 or 6-membered monocyclic ring containing 1, 2, or 3 heteroatoms selected from N, O, and S, the phenyl, benzyl C1-6alk, and unsaturated 5 or 6-membered monocyclic ring being substituted by 0, 1, 2 or 3 substituents selected from halo, cyano, oxo, C1-4alk, C1-4alkOH, C1-3haloalk, —OC1-4alk, —OH, —NH2, —OC1-4alk, —OC1-4haloalk, —S(═O)2C1-4alk, —NHC(═O)—C1-4alk, —C(═O)NH2, —C(═O)NHC1-4alk, —C(═O)N(C1-4alk)2, —NHC1-4alk, and —N(C1-4alk)C1-4alk, or a saturated, partially-saturated, or unsaturated 5 or 6-membered monocyclic ring containing 1 or 2 heteroatoms selected from N, O, and S;
wherein the compound is not one of the following compounds and is not a salt thereof:
and further wherein, the compound is not one of the following compounds, is not a salt thereof, is not a tautomer thereof, is not a salt of a tautomer, is not a stereoisomer thereof, and is not a salt of a stereoisomer:

### Claim 2 (depends on 1)

The compound of claim 1 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, wherein R7 and R8 are selected from H and —CH3.

### Claim 3 (depends on 1)

The compound of claim 1 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, wherein m is 1.

### Claim 4 (depends on 1)

The compound of claim 1 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, wherein Y is —O—.

### Claim 5 (depends on 1)

The compound of claim 1 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, wherein R9 and R10 are H.

### Claim 6 (depends on 1)

The compound of claim 1 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, wherein the compound of Formula I has the Formula II:
wherein:
Y is selected from —O— or —CH2—.

### Claim 7 (depends on 6)

The compound of claim 6 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, wherein the compound of Formula II has the Formula IIA:

### Claim 8 (depends on 7)

The compound of claim 7 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, wherein 1 of X1, X2, X3, and X4 is N.

### Claim 9 (depends on 7)

The compound of claim 7 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, wherein X1 is N and X2, X3, and X4 are all —CR5—.

### Claim 10 (depends on 8)

The compound of claim 8 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, wherein 0 or 1 of Z1, Z2, and Z3 are N.

### Claim 11 (depends on 10)

The compound of claim 10 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, wherein 0 of Z1, Z2, and Z3 are N.

### Claim 12 (depends on 1)

The compound of claim 1 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, wherein V is —C(═O)—.

### Claim 13 (depends on 12)

The compound of claim 12 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, wherein W is absent.

### Claim 14 (depends on 3)

The compound of claim 3 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, wherein R2 is H.

### Claim 15 (depends on 1)

The compound of claim 1 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, wherein the compound of Formula I has the Formula III
wherein Y is —O— or —CH2—.

### Claim 16 (depends on 1)

The compound of claim 1 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, wherein R3 is selected from —CH3, —F, —Cl, —CF3, or —OCF3.

### Claim 17 (depends on 16)

The compound of claim 16 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, wherein R3 is selected from —CF3 or —OCF3.

### Claim 18 (depends on 1)

The compound of claim 1 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, wherein R3 is Rb and Rb is a phenyl substituted by 0, 1, 2 or 3 substituents selected from halo, cyano, oxo, C1-4alk, C1-4alkOH, C1-3haloalk, —OC1-4alk, —OH, —NH2, —OC1-4alk, —OC1-4haloalk, —S(═O)2C1-4alk, —NHC(═O)—C1-4alk, —C(═O)NH2, —C(═O)NHC1-4alk, —C(═O)N(C1 -4-alk)2, —NHC1-4alk, and —N(C1-4alk)C1-4alk, or a saturated, partially-saturated, or unsaturated 5 or 6-membered monocyclic ring containing 1 or 2 heteroatoms selected from N, O, and S.

### Claim 19 (depends on 1)

The compound of claim 1 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, wherein R3 is Rb and Rb is an unsaturated 5 or 6-membered monocyclic ring containing 1, 2, or 3 heteroatoms selected from N, O, and S, wherein the 5 or 6-membered monocyclic ring is substituted by 0. 1, 2, or 3 substituents selected from halo, cyano, oxo, C1-4alk, C1-4alkOH, C1-3haloalk, —OC1-4alk, —OH, —NH2, —OC1-4alk, —OC1-4haloalk, —S(═O)2Cl1-4alk, —NHC(═O)—C1-4alk, —C(═O)NH2, —C(═O)NHC1-4alk, —C(═O)N(C1 -4-alk)2, —NHC1-4alk, and —N(C1-4alk)C1-4alk, or a saturated, partially-saturated, or unsaturated 5 or 6-membered monocyclic ring containing 1 or 2 heteroatoms selected from N, O, and S.

### Claim 20 (depends on 1)

The compound of claim 1 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, wherein R3 is Rb and Rb is a pyridyl, pyrazinyl, pyrimidinyl, isoxazolyl, or furanyl substituted by 0. 1, 2, or 3 substituents selected from halo, cyano, oxo, C1-4alk, C1-4alkOH, C1-3haloalk, —OC1-4alk, —OH, —NH2, —OC1-4alk, —OC1-4haloalk, —S(═O)2C1-4alk, —NHC(═O)—C1-4alk, —C(═O)NH2, —C(═O)NHC1-4alk, —C(═O)N(C1-4alk)2, —NHC1-4alk, and —N(C1-4alk)C1-4alk, or a saturated, partially-saturated, or unsaturated 5 or 6-membered monocyclic ring containing 1 or 2 heteroatoms selected from N, O, and S.

### Claim 21 (depends on 1)

The compound of claim 1 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, wherein R4 is H.

### Claim 22 (depends on 1)

The compound of claim 1 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, wherein R4 is selected from F, Cl, C1-6alk, —OC1-balk, —OC1-3haloalk, or —C1-3haloalk.

### Claim 23 (depends on 1)

The compound of claim 1 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, wherein R4 is —F.

### Claim 24 (depends on 1)

The compound of claim 1 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, wherein —R3 is —OCF3 and R4 is —F.

### Claim 25 (depends on 1)

The compound of claim 1 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, wherein each instance of R5 is H.

### Claim 26 (depends on 1)

The compound of claim 1 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, wherein in at least one instance, R5 is selected from C1-8alk, halo, or —ORa.

### Claim 27 (depends on 1)

The compound of claim 1 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, wherein in at least one instance, R5 is selected from —CH3, —Cl, —F, or —OMe.

### Claim 28 (depends on 1)

The compound of claim 1 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, wherein each instance of R6 is H.

### Claim 29 (depends on 1)

The compound of claim 1 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, wherein at least one instance of R6 is halo or C1-6alk.

### Claim 30 (depends on 1)

The compound of claim 1 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, wherein R1 is the saturated, partially-saturated or unsaturated 3-, 4-, 5-, 6- or 7-membered monocyclic or 7-, 8-, 9-, 10- or 11-membered bicyclic ring and the monocyclic or bicyclic ring is substituted by 0, 1, 2, or 3 substituents, wherein the substituents are selected from F, Cl, Br, I, oxo, cyano, —CH3, —CH2CH3, —CH2CH2CH3, —C(H)(CH3)2, —CH2C(H)(CH3)2, —CH2C(H)═CH2, —CH2CO2H, —CH2CF3, —C(OH)(CH3)2, —SO2N(H)CH3, —N(H)SO2CH3, —OCH3, —OCF3, —OH, —OCH2CO2H, —CH2OH, —CH2CH2OH, —CH2C(H)(CH3)OH, —CO2H, —CO2CH3, —CO2CH2CH3, —CO2C(CH3)3, —CO2NH2, —CO2N(H)CH3, —SO2CH3, —OC(═O)CH3, —NH2, —NHC(═O)CH3, —N(CH3)2, —N(H)CH2CH3, —CF3, —CHF2, —CH2C(H)(CF3)OH, —CH2C(CH3)2OH, —CH2-phenyl, —C(═O)-phenyl, tetrazolyl, oxadiazolonyl, pyridyl, oxetanyl,

### Claim 31 (depends on 1)

The compound of claim 1 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, wherein R1 is a phenyl, pyridyl, pyridinonyl, piperidinonyl, pyridazinonyl, pyrazinonyl, pyridazinyl, pyrimidinyl, pyrazinyl, tetradyrofuranyl, tetrahydropyranyl, thiazolyl, isothiazolyl, furanyl, thiophenyl, pyrazolyl, isoxazolyl, triazolyl, oxazolyl, imidazolyl, pyrrolidinonyl, piperidinyl, cyclohexyl, cyclohexanonyl, quinolinyl, isoquinolinyl, naphthyridinyl, pyrrolopyridinyl, pyrrolopyrimidinyl, benzothiophenyl, pyrazolopyrimidinyl, triazolopyrimidinyl, indazolyl, tetrahydroindazolyl, tetrahydrocyclopentapyrazolyl, dihydropyrazolooxazinyl, indolinonyl, isoindolinonyl, benzooxazolonyl, oxazolopyridinonyl, benzoimidazolonyl, isoindolindionyl, tetrahydroquinolinyl, dihydroquinolinonyl, benzooxazinonyl, dihydrobenzooxazinonyl, dihydroindenonyl, benzothiazolyl, benzimidazolyl, imidazopyridinyl, tetrazolopyridinyl, quinolinonyl, quinoxalinyl, indolyl, or quinoxalindionyl substituted by 0, 1, 2, or 3 substituents.

### Claim 32 (depends on 1)

The compound of claim 1 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, wherein R1 is a phenyl, pyridyl, pyridinonyl, pyrazinonyl, pyridazinyl, pyrimidinyl, tetrahydropyranyl, thiazolyl, isothiazolyl, imidazolyl, piperidinyl, quinolinyl, isoquinolinyl, indazolyl, indolinonyl, isoindolinonyl, benzooxazolonyl, dihydroquinolinonyl, imidazopyridinyl, quinolinonyl, indolyl substituted by 0, 1, 2, or 3 substituents.

### Claim 33 (depends on 32)

The compound of claim 32 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, wherein R1 is a phenyl substituted by 0, or 1 substituent.

### Claim 34 (depends on 32)

The compound of claim 32 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, wherein R1 is a pyridinonyl substituted by 0, or 1 substituent.

### Claim 35 (depends on 32)

The compound of claim 32 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, wherein R1 is a pyridyl substituted by 0, or 1 substituent.

### Claim 36 (depends on 32)

The compound of claim 32 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, wherein R1 is a benzooxazolonyl substituted by 0, or 1 substituent.

### Claim 37 (depends on 32)

The compound of claim 32 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, wherein R1 is a quinolinyl substituted by 0, or 1 substituent.

### Claim 38 (depends on 1)

The compound of claim 1 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, wherein R1 is a group of formula
the symbol , when drawn across a bond, indicates the point of attachment to the rest of the molecule.

### Claim 39 (depends on 1)

The compound of claim 1 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, wherein R1 is a group of formula
the symbol , when drawn across a bond, indicates the point of attachment to the rest of the molecule.

### Claim 40 (depends on 1)

The compound of claim 1 or the pharmaceutically-acceptable salt hereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, wherein R1 is a group of formula
and the symbol , when drawn across a bond, indicates the point of attachment to the rest of the molecule.

### Claim 41 (depends on 1)

The compound of claim 1 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, wherein R1 is
and the symbol , when drawn across a bond, indicates the point of attachment to the rest of the molecule.

### Claim 42 (depends on 1)

The compound of claim 1 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, wherein R1 is
and the symbol , when drawn across a bond, indicates the point of attachment to the rest of the molecule.

### Claim 43 (depends on 1)

The compound of claim 1 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, wherein R1 is
and the symbol , when drawn across a bond, indicates the point of attachment to the rest of the molecule.

### Claim 44 (depends on 1)

The compound of claim 1 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, wherein R1 is
and the symbol , when drawn across a bond, indicates the point of attachment to the rest of the molecule.

### Claim 45 (depends on 1)

The compound of claim 1 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, wherein R1 is
and the symbol , when drawn across a bond, indicates the point of attachment to the rest of the molecule.

### Claim 46 (depends on 1)

The compound of claim 1, wherein the compound is
(S)-1-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-3-(pyrazin-2-yl)urea;
(S)-1-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-3-(pyrimidin-2-yl)urea;
(S)-methyl 6-(3-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)ureido)nicotinate;
(S)-1-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-3-(pyrimidin-5-yl)urea;
(S)-methyl 2-(3-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)ureido)benzoate;
(S)-methyl 5-(3-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)ureido)picolinate;
(S)-1-(6-bromopyridin-3-yl)-3-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)urea;
(S)-1-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-3-(pyrimidin-4-yl)urea;
(S)-methyl 4-(3-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)ureido)benzoate;
(S)-methyl 3-(3-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)ureido)benzoate;
(S)-1-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-3-(pyridin-3-yl)urea;
(S)-1-(2-bromopyridin-3-yl)-3-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)urea;
(S)-1-(4-bromopyridin-3-yl)-3-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)urea;
(S)-1-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-3-(pyridin-2-yl)urea;
(S)-1-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-3-(pyridin-4-yl)urea;
(S)-1-(3,5-difluoro-4-hydroxyphenyl)-3-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)urea;
(S)—N-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)piperidine-1-carboxamide;
(S)-methyl 1-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)piperidine-4-carboxylate;
(S)-4,4-difluoro-N-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)piperidine-1-carboxamide;
(S)—N-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)morpholine-4-carboxamide;
(S)—N-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-4-hydroxypiperidine-1-carboxamide;
(S)—N-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-4-oxopiperidine-1-carboxamide;
(S)—N-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)pyrrolidine-1-carboxamide;
(S)—N-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)azetidine-1-carboxamide;
(S)-2-(3-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)ureido)benzoic acid;
(S)-3-(3-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)ureido)benzoic acid;
(S)-4-(3-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)ureido)benzoic acid;
(S)-1-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-3-(6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-3-yl)urea;
(S)-1-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)piperidine-4-carboxylic acid;
(S)—N-(4-(4-(cyanomethyl)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-4-fluorobenzamide;
(S)-4-fluoro-N-(4-(4-(pyridin-2-yl)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)benzamide;
(S)—N-(4-([1,1′-biphenyl]-4-yl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-4-fluorobenzamide;
(S)-4-fluoro-N-(4-(4′-fluoro-[1,1′-biphenyl]-4-yl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)benzamide;
(S)-4-fluoro-N-(4-(4-(pyridin-3-yl)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)benzamide;
(S)-4-fluoro-N-(4-(4-(pyridin-4-yl)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)benzamide;
(S)—N-(4-(4-(5-ethoxypyrazin-2-yl)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-4-fluorobenzamide;
(S)-4-fluoro-N-(4-(3′-(hydroxymethyl)-[1,1′-biphenyl]-4-yl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)benzamide;
(S)-4-fluoro-N-(4-(4′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)benzamide;
(S)-4-fluoro-N-(4-(2′-hydroxy-[1,1′-biphenyl]-4-yl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)benzamide;
(S)—N-(4-(4′-acetamido-[1,1′-biphenyl]-4-yl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-4-fluorobenzamide;
(S)-4-fluoro-N-(4-(4′-fluoro-3′-(hydroxymethyl)-[1,1′-biphenyl]-4-yl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)benzamide;
(S)-4-chloro-4′-(4-(4-fluorobenzamido)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-[1,1′-biphenyl]-3-carboxamide;
(S)-4-fluoro-N-(4-(4-(pyrimidin-5-yl)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)benzamide;
(S)—N-(4-(4-(3,5-dimethylisoxazol-4-yl)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-4-fluorobenzamide;
(S)—N-(4-(3′-amino-[1,1′-biphenyl]-4-yl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-4-fluorobenzamide;
(S)-4-fluoro-N-(4-(4-(2-methoxypyrimidin-5-yl)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)benzamide;
(S)-4-fluoro-N-(4-(2′-(hydroxymethyl)-[1,1′-biphenyl]-4-yl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)benzamide;
(S)-4′-(4-(4-fluorobenzamido)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-N,N-dimethyl-[1,1′-biphenyl]-3-carboxamide;
(S)-4-fluoro-N-(4-(4-(4-methoxypyridin-3-yl)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)benzamide;
(S)-4-fluoro-N-(4-(4-(2-methoxypyridin-3-yl)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)benzamide;
(S)-4-fluoro-N-(4-(4-(4-methylpyridin-3-yl)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)benzamide;
(S)-4-fluoro-N-(4-(4′-morpholino-[1,1′-biphenyl]-4-yl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)benzamide;
(S)-4-fluoro-N-(4-(3′-fluoro-2′-hydroxy-[1,1′-biphenyl]-4-yl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)benzamide;
(S)-4-fluoro-N-(4-(2′-hydroxy-3′-methoxy-[1,1′-biphenyl]-4-yl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)benzamide;
(S)-4-fluoro-N-(4-(2′-(hydroxymethyl)-4′-methoxy-[1,1′-biphenyl]-4-yl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)benzamide;
(S)-4′-(4-(4-fluorobenzamido)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-N,N-dimethyl-[1,1′-biphenyl]-4-carboxamide;
(S)-4′-(4-(4-fluorobenzamido)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-N-methyl-[1,1′-biphenyl]-4-carboxamide;
(S)—N-(4-(4-(2-chloropyrimidin-5-yl)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-4-fluorobenzamide;
(S)-4-fluoro-N-(4-(5′-fluoro-2′-(hydroxymethyl)-[1,1′-biphenyl]-4-yl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)benzamide;
(S)—N-(4-(4-(5-cyanopyridin-3-yl)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-4-fluorobenzamide;
(S)-4-fluoro-N-(4-(3′-morpholino-[1,1′-biphenyl]-4-yl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)benzamide;
(S)—N-(4-(2′-amino-[1,1′-biphenyl]-4-yl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-4-fluorobenzamide;
(S)-4-fluoro-N-(4-(2′-(methylsulfonyl)-[1,1′-biphenyl]-4-yl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)benzamide;
(S)-4-fluoro-N-(4-(4-(furan-3-yl)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)benzamide;
(S)-4-fluoro-N-(4-(4-(2-methoxypyridin-4-yl)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)benzamide;
(S)—N-(4-(4′-amino-[1,1′-biphenyl]-4-yl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-4-fluorobenzamide;
(S)—N-(4-(3′-amino-4′-methyl-[1,1′-biphenyl]-4-yl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-4-fluorobenzamide;
(S)—N-(4-(4-(2,4-dimethoxypyrimidin-5-yl)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-4-fluorobenzamide;
(S)-4-fluoro-N-(4-(3′-(5-methyl-1,3,4-oxadiazol-2-yl)-[1,1′-biphenyl]-4-yl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)benzamide;
(S)-4-fluoro-N-(4-(4′-(hydroxymethyl)-[1,1′-biphenyl]-4-yl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)benzamide;
(R)—N—((S)-4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-2-methylpropane-2-sulfinamide;
(S)—N-(4-(4′-cyano-[1,1′-biphenyl]-4-yl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-4-fluorobenzamide;
(S)—N-(4-(4′-cyano-[1,1′-biphenyl]-4-yl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)benzamide;
(S)—N-(4-(4′-cyano-[1,1′-biphenyl]-4-yl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-2-oxo-2,3-dihydrobenzo[d]oxazole-5-carboxamide 2,2,2-trifluoroacetate;
(S)-4-acetyl-N-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)benzamide;
N—((S)-4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-4-((R)-1-hydroxyethyl)benzamide and N—((S)-4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-4-((S)-1-hydroxyethyl)benzamide;
(S)—N-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-4-(hydroxymethyl)benzamide;
N—((S)-4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-4-((R)-2,2,2-trifluoro-1-hydroxyethyl)benzamide and N—((S)-4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-4-((S)-2,2,2-trifluoro-1-hydroxyethyl)benzamide;
(S)—N-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-4-(2,2,2-trifluoroacetyl)benzamide;
(R)-6-((3-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2,3-dihydrofuro[3,2-b]pyridin-3-yl)carbamoyl)nicotinic acid;
(S)-ethyl 5-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)-1H-imidazole-2-carboxylate;
(S)—N-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-1-methyl-1H-imidazole-5-carboxamide;
(S)—N-(8-(3-fluoro-4-(trifluoromethoxy)phenyl)-7,8-dihydro-6H-pyrano[2,3-b]pyrazin-8-yl)-6-oxo-1,6-dihydropyridine-3-carboxamide;
(S)—N-(7-(3-fluoro-4-(trifluoromethoxy)phenyl)-5-oxo-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl)-6-oxo-1,6-dihydropyridine-3-carboxamide;
(S)-5-bromo-N-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-4-methylpicolinamide;
(S)-4-bromo-N-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-3-methylbenzamide;
(S)-4-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)-N-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)benzamide;
(S)-ethyl 6-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)-2-methylnicotinate;
(S)-5-cyano-N-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)picolinamide;
(S)-methyl 6-((4-(3-fluoro-4-(trifluoromethyl)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)nicotinate;
(S)-methyl 6-((4-(2-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)nicotinate;
(S)-methyl 6-((4-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)nicotinate;
(S)-methyl 6-((4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)nicotinate;
(S)-5-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)pyrazine-2-carboxylic acid;
(S)-3-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)benzoic acid;
(S)—N-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-1-methyl-1H-imidazole-4-carboxamide;
(S)-2-bromo-N-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-1-methyl-1H-imidazole-5-carboxamide;
(S)-methyl 4-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)-2,6-dimethylbenzoate;
(S)-methyl 5-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)-2-methoxybenzoate;
(S)-methyl 6-((4-(3,4-dichlorophenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)nicotinate;
(S)—N-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-4-sulfamoylbenzamide;
(S)—N-(4-(4-fluoro-3-(trifluoromethyl)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-6-oxo-1,6-dihydropyridine-3-carboxamide;
(S)-3-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)-2-methoxybenzoic acid;
(S)-ethyl 4-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)-1H-pyrrole-2-carboxylate;
(S)-methyl 2-amino-4-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)benzoate;
(S)—N-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)oxazole-2-carboxamide;
(S)—N-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)isothiazole-4-carboxamide;
(S)-methyl 2-ethyl-4-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)benzoate;
(S)-diethyl 5-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)isophthalate;
(S)-methyl 1-(2-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)amino)-2-oxoethyl)-1H-pyrrole-3-carboxylate;
(S)—N1-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)terephthalamide;
(S)-methyl 6-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)-1-methyl-1H-indole-2-carboxylate;
(S)-2-chloro-4-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)benzoic acid;
(S)—N-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)thiazole-4-carboxamide;
(S)—N-(4-(3-methyl-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-6-oxo-1,6-dihydropyridine-3-carboxamide;
(S)-5-chloro-N-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)isoxazole-3-carboxamide;
(S)-methyl 2-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)isonicotinate;
N—((S)-4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-1-((R)-2-hydroxypropyl)-6-oxo-1,6-dihydropyridine-3-carboxamide;
(S)-5-bromo-N-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)thiophene-2-carboxamide;
(S)-4-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)benzoic acid;
(S)-3,5-difluoro-4-hydroxy-N-(4-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)benzamide;
(S)-5-bromo-N-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)picolinamide;
(S)-3,5-difluoro-N-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-4-hydroxybenzamide;
(S)-5-bromo-N-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)furan-2-carboxamide;
(S)-methyl 6-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)-1H-indole-2-carboxylate;
(S)—N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-1H-imidazole-2-carboxamide;
(S)—N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-1H-pyrazole-3-carboxamide;
(S)—N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-4H-1,2,4-triazole-3-carboxamide;
(S)—N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)isothiazole-5-carboxamide;
(S)—N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-1,2,3-thiadiazole-5-carboxamide;
(S)—N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-1H-indazole-5-carboxamide;
(S)—N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-1H-pyrrolo[2,3-b]pyridine-2-carboxamide;
(S)—N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide;
(S)—N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-1H-pyrrolo[2,3-b]pyridine-4-carboxamide;
(S)—N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)pyrazolo[1,5-a]pyridine-2-carboxamide;
(S)—N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide;
(S)—N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)quinoline-8-carboxamide;
(S)-5-methyl-N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-1H-indole-2-carboxamide;
(S)-1-oxo-N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-1,2-dihydroisoquinoline-6-carboxamide;
(S)-7-cyclopropyl-N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)pyrazolo[1,5-a]pyrimidine-2-carboxamide;
(S)-7-methoxy-N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)quinoline-3-carboxamide;
(S)—N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)oxazole-4-carboxamide;
(S)-1-methyl-N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-1H-pyrazole-3-carboxamide;
(S)-1-methyl-N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-1H-pyrazole-5-carboxamide;
(S)—N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)thiophene-2-carboxamide;
(S)—N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)thiophene-3-carboxamide;
(S)—N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)thiazole-4-carboxamide;
(S)—N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)isothiazole-3-carboxamide;
(S)—N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)thiazole-5-carboxamide;
(S)—N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-1H-indole-3-carboxamide;
(S)—N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-1H-indole-6-carboxamide;
(S)—N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)benzofuran-2-carboxamide;
(S)—N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-1H-benzo[d]imidazole-5-carboxamide;
(S)—N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-1H-benzo[d]imidazole-4-carboxamide;
(S)—N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)imidazo[1,2-a]pyridine-2-carboxamide;
(S)—N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)imidazo[1,2-a]pyridine-6-carboxamide;
(S)—N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-1H-benzo[d]imidazole-2-carboxamide;
(S)—N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide;
(S)—N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)imidazo[1,2-b]pyridazine-2-carboxamide;
(S)—N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide;
N—-((S)-4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)indoline-2-carboxamide;
N—-((S)-4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-2,3-dihydrobenzofuran-2-carboxamide;
(S)—N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)isoquinoline-1-carboxamide;
(S)—N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)isoquinoline-3-carboxamide;
(S)—N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)isoquinoline-5-carboxamide;
(S)—N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)isoquinoline-6-carboxamide;
(S)—N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)quinoline-2-carboxamide;
(S)—N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)quinoline-3-carboxamide;
(S)—N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)quinoline-6-carboxamide;
(S)—N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)quinoline-7-carboxamide;
(S)—N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)quinoxaline-2-carboxamide;
(S)-1-methyl-N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-1H-indole-2-carboxamide;
(S)-1-methyl-N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-1H-indole-3-carboxamide;
(S)-1-methyl-N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-1H-indole-5-carboxamide;
(S)—N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-2H-chromene-3-carboxamide;
(S)-1-methyl-N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-1H-benzo[d]imidazole-2-carboxamide;
(S)-1-methyl-N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-1H-indazole-4-carboxamide;
(S)-1-methyl-N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-1H-indazole-5-carboxamide;
(S)-1-methyl-N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-1H-indazole-6-carboxamide;
(S)-2-methyl-N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-2H-indazole-4-carboxamide;
(S)-2-methyl-N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-2H-indazole-6-carboxamide;
(S)-2-methyl-N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-2H-indazole-7-carboxamide;
(S)—N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)benzo[b]thiophene-2-carboxamide;
(S)—N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyrid in-4-yl)benzo[b]thiophene-3-carboxamide;
(S)—N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)benzo[c][1,2,5]thiadiazole-5-carboxamide;
(S)-2-methyl-N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-4,5,6,7-tetrahydro-2H-indazole-3-carboxamide;
(S)-1-oxo-N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-1,2-dihydroisoquinoline-7-carboxamide;
(S)-1-oxo-N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-1,2-dihydroisoquinoline-4-carboxamide;
(S)-4-(oxazol-5-yl)-N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)benzamide;
(S)-5-methoxy-N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-1H-pyrrolo[2,3-c]pyridine-2-carboxamide;
(S)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)benzamide;
(S)-4-(5-methyl-1,2,4-oxadiazol-3-yl)-N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)benzamide;
(S)-3-(2-oxopyrrolidin-1-yl)-N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)benzamide;
(S)-6-methoxy-N-(4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-2H-chromene-3-carboxamide;
(S)-ethyl 4-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)thiazole-2-carboxylate;
(S)-methyl 3-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)benzoate;
(S)—N-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-5-(2H-tetrazol-5-yl)picolinamide;
(S)—N-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-5-(1,2,4-oxadiazol-3-yl)picolinamide;
(S)—N-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)picolinamide;
(S)-5-amino-N-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)picolinamide;
(S)-methyl 3-(N-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)sulfamoyl)benzoate;
(S)-methyl 4-(N-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)sulfamoyl)benzoate;
(S)-4-((4-(3-fluoro-4-(trifluoromethyl)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)-2-methylbenzoic acid;
(S)-2-methyl-4-((4-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)benzoic acid;
(S)-4-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)-2-vinylbenzoic acid;
(S)-5-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)-[1,1′-biphenyl]-2-carboxylic acid;
(S)-2-ethyl-4-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)benzoic acid;
(S)-4-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)-2-isopropylbenzoic acid;
(S)-4-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)-2-isobutylbenzoic acid;
(S)-4-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)-2-(methylamino)benzoic acid;
(S)-methyl 2-acetamido-4-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)benzoate;
(S)—N4-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-N1,2-dimethylterephthalamide;
(S)—N1-(tert-butyl)-N4-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-2-methylterephthalamide;
(S)-4-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)-2-hydroxybenzoic acid;
(S)-4-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)-1-methyl-1H-pyrrole-2-carboxylic acid;
(S)-2-cyclopropyl-4-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)benzoic acid;
(S)-5-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)-2-methyl-1H-pyrrole-3-carboxylic acid;
(S)-2-(cyclopropylamino)-4-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)benzoic acid;
(S)-5-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)-1,2-dimethyl-1H-pyrrole-3-carboxylic acid;
(S)-2-fluoro-4-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)-6-(methylamino)benzoic acid;
(S)-methyl 5-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)-1-methyl-1H-pyrrole-2-carboxylate;
(S)-5-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)-1H-pyrrole-2-carboxylic acid;
(S)—N2-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-N5-(phenylsulfonyl)pyridine-2,5-dicarboxamide;
(S)—N-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)furan-2-carboxamide;
(S)—N1-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-N3-methylisophthalamide;
(S)-6-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)-2-methylnicotinic acid;
(S)-4-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)-2,6-dimethylbenzoic acid;
(S)-4-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)-3-methoxybenzoic acid;
(S)-5-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)-2-methoxybenzoic acid;
(S)-3-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)-4-methoxybenzoic acid;
(S)-4-(N-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)sulfamoyl)benzoic acid;
(S)-2-methyl-4-((4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)benzoic acid;
(S)-4-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)-1H-pyrrole-2-carboxylic acid;
(S)-2-amino-4-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)benzoic acid;
(S)-6-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)-1-methyl-1H-indole-2-carboxylic acid;
(S)-2-acetamido-4-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)benzoic acid;
(S)-5-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)-1-methyl-1H-pyrrole-2-carboxylic acid;
(S)-6-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)-1H-indole-2-carboxylic acid;
(S)-5-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)picolinic acid;
(S)-4-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)thiazole-2-carboxylic acid;
(S)-2-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)isonicotinic acid;
(S)-2-fluoro-4-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)benzoic acid;
(S)-4-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)-2-methylbenzoic acid;
(S)-6-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)-4-methylnicotinic acid;
(S)-5-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)-1H-pyrrole-3-carboxylic acid;
(S)-5-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)-1-methyl-1H-pyrrole-3-carboxylic acid;
(S)-5-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)thiophene-2-carboxylic acid; or
(S)-4-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)-2-methoxybenzoic acid; or
the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof.

### Claim 47 (depends on 1)

The compound of claim 1, wherein the compound is
(S)-1-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-3-(pyrimidin-2-yl)urea;
(S)-1-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-3-(pyrimidin-5-yl)urea;
(S)—N-(4-(4′-cyano-[1,1′-biphenyl]-4-yl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-2-oxo-2,3-dihydrobenzo[d]oxazole-5-carboxamide;
(S)—N-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-4-(hydroxymethyl)benzamide;
(S)-4-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)benzoic acid;
(S)—N-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)picolinamide;
(S)-4-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)-2-vinylbenzoic acid;
(S)-2-ethyl-4-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)benzoic acid;
(S)-6-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)-2-methylnicotinic acid;
(S)-4-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)-3-methoxybenzoic acid;
(S)-2-methyl-4-((4-(4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)benzoic acid;
(S)-2-amino-4-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)benzoic acid;
(S)-6-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)-1-methyl-1H-indole-2-carboxylic acid; or
(S)-4-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)-2-methylbenzoic acid; or
the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof.

### Claim 48 (depends on 1)

The compound of claim 1, wherein the compound is (S)—N-(4-(4′-cyano-[1,1′-biphenyl]-4-yl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-2-oxo-2,3-dihydrobenzo[d]oxazole-5-carboxamide, or
the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof.

### Claim 49 (depends on 1)

The compound of claim 1, wherein the compound is (S)-1-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-3-(pyrimidin-2-yl)urea, or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof.

### Claim 50 (depends on 1)

The compound of claim 1, wherein the compound is (S)—N-(4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)picolinamide, or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof.

### Claim 51 (depends on 1)

The compound of claim 1, wherein the compound is (S)-2-ethyl-4-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)benzoic acid, or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof.

### Claim 52 (depends on 1)

The compound of claim 1, wherein the compound is (S)-4-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)-3-methoxybenzoic acid, or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof.

### Claim 53 (depends on 1)

The compound of claim 1, wherein the compound is (S)-6-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)-1-methyl-1H-indole-2-carboxylic acid, or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof.

### Claim 54 (depends on 1)

The compound of claim 1, wherein the compound is (S)-2-amino-4-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)benzoic acid, or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof.

### Claim 55 (depends on 1)

The compound of claim 1, wherein the compound is (S)-4-((4-(3-fluoro-4-(trifluoromethoxy)phenyl)-3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-yl)carbamoyl)-2-methylbenzoic acid, or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof.

### Claim 56 (depends on 1)

The compound or tautomer of claim 1 in a neutral form.

### Claim 57 (depends on 1)

The pharmaceutically-acceptably salt of the compound or the pharmaceutically acceptable salt of the tautomer of claim 1.

### Claim 58 (depends on 1)

A pharmaceutical composition comprising the compound according to claim 1 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof, and a pharmaceutically-acceptable diluent or carrier.

### Claim 59 (depends on 1)

A method of treating acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, depression, anxiety, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders in a subject, the method comprising administering the compound according to claim 1 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, the stereoisomer thereof, or the mixture thereof to the subject.

### Claim 60 (depends on 59)

The method of claim 59, wherein the subject is suffering from migraine pain.
